Find company announcements below, or check out the latest news in the right side menu.
30. April 2013
Print Share this Updated Financial calendar 2013 Novozymes hereby publishes its updated financial calendar for the remainder of Fiscal year 2013 30. April 2013 Page Content August 9, 2013 Interim report for the first half of 2013 October 25, 2013 Interim report for the first nine months of 2013
25. April 2013
The first quarter of 2013 was in line with expectations. Organic sales growth was 5% (4% DKK, 5% LCY) compared with Q1 2012. EBIT grew by 4%, and the EBIT margin was 24.9% – on par with the first quarter of 2012.
5. April 2013
With reference to company announcement no. 15/2013, a reduction of the company’s B share capital by DKK 10,600,000 via cancellation of 5,300,000 treasury B shares, was adopted at Novozymes A/S’ Annual Shareholders’ Meeting on February 28, 2013.
1. March 2013
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.
28. February 2013
Reduction of the company’s share capital by cancellation of a part of its holding of treasury B shares. The company’s B share capital is reduced by DKK 10,600,000 from DKK 542,512,800 to DKK 531,912,800.
22. February 2013
In reference to company announcement no. 4 of January 31, 2013, the closing conditions for the transaction have been met, and the acquisition of the enzymes business of Iogen Corporation by Novozymes has been completed.
18. February 2013
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B
15. February 2013
14. February 2013
12. February 2013
8. February 2013
6. February 2013
5. February 2013
1. February 2013
Election of employee representatives to the Board of Directors of Novozymes AS
31. January 2013
Novozymes acquires Iogen Bio-Products, the industrial enzyme business of Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370 million) and potential earn-out payments of up to CAD 12.5 million (approximately DKK 70 million).
21. January 2013
Organic sales growth was 4% (7% DKK, 3% LCY) compared with 2011. EBIT increased by 17%, raising the EBIT margin to 24.4%. Net profit grew by 10%. Strong free cash flow before acquisitions of DKK 1,581 million exceeded the outlook.
He holds a M.Sc. and Ph.D. in Chemical Engineering from the Technical University of Denmark, and a B.Com. in International Business Management from the Copenhagen Business School.
7. January 2013
Print Share this Financial calendar 2013 Novozymes hereby publishes its financial calendar for 2013 7. January 2013 Page Content February 28, 2013 Annual Shareholders' Meeting 2013 April 25, 2013 Interim report for the first three months of 2013 August 9, 2013 Interim report for the first half of
9. November 2012
In accordance with section 29 of the Danish Securities Trading Act, Novozymes has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Ltd, has decreased its holding of B shares in Novozymes to 7.56%
6. November 2012
In reference to company announcement no. 68 of October 29 2012, the closing conditions for the transaction have been met, and the transaction between Novozymes and Beta Renewables has now been closed. Following the transaction, Novozymes’ share of ownership of Beta Renewables is 9.95%.
29. October 2012
Companies enter into strategic partnership making Novozymes the preferred enzyme supplier for Beta Renewables’ current and future cellulosic biofuel projects.
With the announcement today of the strategic partnership with and acquisition of a share in Beta Renewables (Company announcement No. 68), the aforementioned share buyback program is hereby terminated.
26. October 2012
On January 20, 2012, Novozymes initiated a share buyback program in accordance with the provisions of European Commission Regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbour Regulation.
1. April 2013
| Copyright © 2010 Novozymes. All Rights Reserved.